MedTrace Logo

Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People

NCT05352867 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2023-09-06

No results posted yet for this study

Summary

Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of the New Coronavirus mRNA Vaccine (LVRNA009) in Chinese People Aged 18\~59 Years

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 (LVRNA009) 50μg group

50μg/person

BIOLOGICAL

SARS-CoV-2 (LVRNA009) 100μg group

100μg/person

OTHER

Placebo

0.5ml/person

Sponsors & Collaborators

  • Hunan Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tao Huang · Hunan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2022-06-23
Completion
2023-06-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05352867 on ClinicalTrials.gov